Lakewood-Amedex Biotherapeutics Inc. (LABT): Form 8-K filed 2026-11-10
- Accepted by EDGAR
- 2026-11-10 17:20 ET
- Event date
- 2026-11-04
- Accession no.
- 0001213900-26-118127
- Original filing
- SEC EDGAR filing index
Items reported
- Item 1.01: Entry into a Material Definitive Agreement
The company signed a material agreement outside the ordinary course of business, or materially amended one. Typical examples are credit agreements, merger agreements, large supply or licensing contracts and financing arrangements. - Item 7.01: Regulation FD Disclosure
The company is making information public under Regulation FD, which requires broad public disclosure of material information shared with certain market participants. Investor presentations and press releases are common. Like Item 2.02, this information is generally "furnished" rather than "filed". - Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | CURRENT REPORT | ea0311576-8k_lakewood.htm |
| EX-99.1 | PRESS RELEASE OF LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC., DATED NOVEMBER 5, 2026 | ea031157601ex99-1.htm |
This page lists what the filing reports; it does not summarize or interpret it. Read the original documents on SEC EDGAR. How to read an 8-K.